Goldline Pharmaceutical Ltd IPO

Experienced promoters and management team with industry knowledge and a track record.

Asset-light business model and competitive products.

Scalable Business Model.

Wide and diverse range of product offerings.

Strong Supplier and Vendor Relationships.

Established Distribution Network.

Its rely entirely on third-party contract manufacturers for the manufacturing of the company pharmaceutical products,and any failure or inability of such manufacturers to meet quality, regulatory, delivery or capacity requirementscould adversely affect its business, results of operations and financial condition.

The Company has experienced delays in filing e-forms with the Registrar of Companies (RoC) in the past, resultingin the payment of late fees. Further, there have also been instances of erroneous filings made by the Company, inthe past. While no regulatory actions or penalties has been imposed to date except below mentioned, there is noassurance that such actions will not be levied in the future. The Company cannot guarantee that similar delayswill not occur in the future, and if regulatory authorities impose penalties or take punitive actions against theCompany or its directors/officers, it could negatively affect the Companys business and financial condition.

The company commercial success is largely dependent upon its ability to analyses the market of new pharmaceuticalproducts, failure of which may has an adverse impact on its revenue and profitability.

There has been instances of delays in payment of statutory dues, i.e. GST by the Company. In case of any delayin payment of statutory due in future by the Company, the Regulatory Authorities may impose monetary penaltieson it or take certain punitive actions against the Company in relation to the same which may has adverse impacton its business, financial condition and results of operations.

Its depend on the company distributors for a significant portion of its revenue, and any decrease in revenues or sales fromany one of the company key intermediaries may adversely affect its business and results of operations. the Company hasa distribution network of 8 distributors and is dependent on these distributors for a significant portion of itsrevenue. If the company unable to maintain its relationship with such customers or if there is a reduction in theirdemand for the company products, its business, results of operations and financial condition will be materially andadversely affected.

There are outstanding mitigations involving the Company, Promoters, Directors, Key Managerial Personnel,Senior Management and Group Companies, if determined adversely, may adversely affect its business and financial condition.

The company Promoter Group entities Numerius Healthcare Private Limited, Nucleage Lifescience Private Limited andNucleage Pharma Solutions Private Limited has conflicts of interest as they are engaged in similar business andmay compete with it.

Its derive a significant portion of the company revenue from certain of its products. If sales volume or price of suchproducts declines in the future, or if the company unable to sell such products for any reason, its business, financialcondition, cash flows and results of operations could be adversely affected.

The company operate in limited geographies for a significant portion of its revenue and also depends on limited number ofcustomers for the company revenue from operations.

The Company had negative cash flows in the past years, details of which are given below. Sustained negative cashflow could impact its growth and business.